# Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan

> **NCT00613028** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 23 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Temo + Avastin
- **DRUG:** VP-16 + Avastin

## Key facts

- **NCT ID:** NCT00613028
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-10
- **Final completion:** 2011-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2013-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00613028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00613028, "Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00613028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*